EPITCER
LIVE

Serial Number

79311194

Owner

NEOGAP Therapeutics AB

Filing Date

Mar 17, 2021

Add to watchlist:

No watchlists yet
View on USPTO

EPITCER Trademark

Serial Number: 79311194 • Registration: 6635212

EPITCER is a trademark filed by NEOGAP Therapeutics AB on March 17, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

NEOGAP Therapeutics AB (3 trademarks)

KAROLINSKA SJUKHUSET L 802 L

Entity Type: 99

Trademark Details

Filing Date

March 17, 2021

Registration Date

February 8, 2022

Published for Opposition

November 23, 2021

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders; immunoassay reagents for medical use

Medical analysis for the diagnosis and treatment of persons; medical services relating to the removal, treatment and processing of human cells; advice relating to immunology

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Mar 21, 2025 NREP
NOTIFICATION PROCESSED BY IB
Jun 12, 2022 GPNX
FINAL DISPOSITION NOTICE SENT TO IB
May 25, 2022 FICS
FINAL DISPOSITION PROCESSED
May 24, 2022 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Mar 10, 2022 GPAR
REGISTERED-PRINCIPAL REGISTER
Feb 8, 2022 R.PR
NOTIFICATION PROCESSED BY IB
Dec 6, 2021 GPNX
PUBLISHED FOR OPPOSITION
Nov 23, 2021 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 17, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 17, 2021 OP2R
NOTICE OF PUBLICATION
Nov 3, 2021 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 21, 2021 PREV
ASSIGNED TO LIE
Oct 21, 2021 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 20, 2021 CNSA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Oct 20, 2021 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 20, 2021 CNSA
ASSIGNED TO EXAMINER
Oct 19, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
May 25, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 21, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 20, 2021 REPR